Evidence mapPaperPMID 42166705Full record

ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2026

Lung Cancer Screening and Prevention: Beyond Conventional Strategies in a Rapidly Changing Global Milieu.

Teresa Gorría, Nicola Marino, Maria Alejandra Montoya Rubiano, Kevin E Salinas, Efrén J Flores, Laura Mezquita, Pan-Chyr Yang

Abstract readReview
In one paragraph

Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Teresa GorríaMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Nicola MarinoYongLin Institute of Health, National Taiwan University, Taipei, Taiwan.
Maria Alejandra Montoya RubianoDepartment of Surgery, Mass General Brigham, MA.
Kevin E SalinasDepartment of Radiology, Mass General Brigham, MA.
Efrén J FloresDepartment of Radiology, Mass General Brigham, MA.
Laura MezquitaMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Pan-Chyr YangYongLin Institute of Health, National Taiwan University, Taipei, Taiwan.ORCID 0000-0001-6330-6048

Funding

Health Opportunities & Promoters of Equitable Screening for Lung Cancer (Hopes for Lung Cancer)K08CA270430 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$281k
NCI NIH HHS K08 CA270430
6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide despite advances in early detection and treatment. Furthermore, its epidemiology has undergone a profound transformation, necessitating a radical and comprehensive departure from traditional oncology frameworks. The historical paradigm, which focuses almost exclusively on tobacco smoking as the primary etiological driver, is increasingly inadequate to address the escalating global burden of lung cancer in never-smokers (LCINS). This epidemiologic shift is particularly evident in East Asian populations, where LCINS has transitioned from being a perceived outlier to becoming the dominant clinical phenotype, representing over 60% of all diagnosed cases in certain demographics especially in women. This comprehensive review integrates the exposome framework: a holistic methodology evaluating the cumulative and synergistic endogenous and environmental impact of air, water, and food pollutants across the human lifespan, with the practical and logistical implementation of precision screening. The addition of humanomics expands the concept of exposome to include societal structural inequalities. Rethinking lung cancer screening beyond a single imaging modality also requires a stronger focus on health equity. By synthesizing longitudinal data from the landmark TALENT study and integrating cutting-edge technologies such as artificial intelligence-driven risk prediction (Sybil) and advanced molecular triage using circulating tumor DNA, we advocate for a radical transition toward comprehensive computed tomography screening. This multisystem approach maximizes public health return on investment by simultaneously intercepting lung cancer, cardiovascular disease, and chronic respiratory illnesses at their earliest preclinical, asymptomatic, and most treatable stages.

Indexed as

Early Detection of CancerLung NeoplasmsFemaleHumansRisk Factors

Identifiers

PMID42166705
PMCPMC13247865

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.